Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades.

Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.

I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for past performance.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cantor Fitzgerald Investment Advisors L.P. lowered its position in shares of AbbVie Inc. (NYSE: ABBV) by 50.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,450 shares of the company's stock after selling 2,450 shares during the quarter.

AMF Tjanstepension AB cut its position in AbbVie Inc. (NYSE: ABBV) by 22.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,119 shares of the company's stock after selling 6,790 shares during the quarter. AMF Tjanstepension

Both companies pay relatively high-yield dividends. One marries this with growing fundamentals, while the other is basically in reset mode.

AbbVie posted strong Phase 2a results for a potential successor to Skyrizi in Crohn's disease. The company also has a promising eczema candidate that could cement its position in immunology.